Purpose Circulating cell-free DNA (cfDNA) is a promising biomarker for predicting treatment
response and disease outcomes in Breast Cancer (BC) patients undergoing neoadjuvant …

Background Although the clinical significance of neoadjuvant chemotherapy (NACT) is
widely recognized, there is still no effective means to monitor the therapeutic response in …

This study aimed to retrospectively evaluate the circulating free DNA (cfDNA) level in
patients with locally advanced breast cancer (LABC) having different neoadjuvant …

Background Circulating cell-free DNA (cfDNA) is a potential non-invasive biomarker of
disease status in patients with cancer, and provides important diagnostic and prognostic …

Purpose: We previously demonstrated the clinical significance of circulating tumor DNA
(ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy …

Background Gene expression profiles in breast tissue biopsies contain information related to
chemotherapy efficacy. The promoter profiles in cell-free DNA (cfDNA) carrying gene …

This study aims to assess cell-free DNA (CFD) by a fluorescence assay as a biomarker for
early prediction of a pathologic complete response (pCR) and relapse in patients with triple …

Background Tumor-derived circulating cell-free DNA (cfDNA) is present in the plasma of
individuals with cancer. Assays aimed at detecting common cancer mutations in cfDNA are …

Background: Circulating cell-free DNA (cfDNA) is a potential biomarker of disease status in
cancer patients and provides valuable diagnostic and prognostic information in breast …

Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is
strongly associated with favorable outcome. We examined the utility of serial circulating …